|
JP2018109039A
|
|
Pharmaceutical composition for relapse, worsening or metastasis of liver cancer
|
|
US2018250317A1
|
|
Muparfostat for use in treating patients with hepatitis virus-related hepatocellular carcinoma after surgical resection
|
|
JP2016199579A
|
|
Pharmaceutical composition for inhibiting recurrence, aggravation, and metastasis of hepatocarcinoma
|
|
US2016185826A1
|
|
Virus-like particle vaccines
|
|
WO2017020570A1
|
|
Virus-like particle vaccines
|
|
US2017051046A1
|
|
H1N1 flu virus neutralizing antibodies
|
|
WO2016019890A1
|
|
Virus-like particle vaccines
|
|
CN105861448A
|
|
Novel enterovirus 71 and application thereof
|
|
TW201615831A
|
|
Novel enterovirus 71 and application thereof
|
|
TW201408321A
|
|
Synergistic combination for treating cancer
|
|
TW201437375A
|
|
System and method for human leukocyte antigen sequencing-based typing
|
|
EP2722049A1
|
|
A pharmaceutical composition for inhibiting recurrence, aggravation and metastasis of hepatocarcinoma
|
|
TW201247208A
|
|
A use of vulcanized oligosaccharide derivatives for inhibiting the recurrence,progression or metastasis of liver cancer
|
|
TW201028470A
|
|
Methods and apparatuses for convective polymerase chain reaction
|
|
NZ587183A
|
|
Methods and apparatuses for convective polymerase chain reaction (pcr)
|
|
US2008020386A1
|
|
Methods and apparatus for genotyping
|
|
GB0606297D0
|
|
Methods and apparatus for genotyping
|
|
US2006068411A1
|
|
Cancer specific gene MH15
|
|
TW200533918A
|
|
Cancer specific gene MG20
|
|
CA2421586A1
|
|
Mucroslysin and its gene
|
